{"url_path":"/sec/armp/8-k/2026-07-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-082850-index.html","accession_number":"0001104659-26-082850","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-082850-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":298,"has_tables":true,"body_markdown":"false\n0000921114\n\n0000921114\n\n2026-07-13\n2026-07-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND\nEXCHANGE COMMISSION**\n\n**Washington, DC\n20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n** **\n\n**Pursuant to Section 13 or 15(d) of\nthe\nSecurities Exchange Act of 1934**\n\n** **\n\nDate of report (Date of earliest event reported):\n**July 13, 2026**\n\n \n\n**ARMATA PHARMACEUTICALS, INC.**\n\n(Exact name of Registrant as specified in\nits charter)\n\n \n\n**Washington**\n \n**001-37544**\n \n**91-1549568**\n\n(State or other jurisdiction\n\nof incorporation or\norganization)\n \n(Commission File Number)\n \n(IRS Employer Identification No.)\n\n \n\n \n**5005 McConnell Avenue**\n\n**** **Los Angeles****, California**\n \n**** **90066**\n\n \n(Address of principal executive offices)\n \n(Zip Code)\n\n** **\n\n**(310) 665-2928**\n\n(Registrant’s Telephone number)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§\n230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the\nregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ¨\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\nTitle\nof Each Class\n \nTrading\nSymbol(s)\n \nName\nof Each Exchange on Which Registered\n\n**Common Stock**\n \n**ARMP**\n \n**NYSE American**"}